Research programme: cardiovascular and metabolic disorder therapeutics - Zealand Pharma/Boehringer Ingelheim

Drug Profile

Research programme: cardiovascular and metabolic disorder therapeutics - Zealand Pharma/Boehringer Ingelheim

Alternative Names: GLP-1/GLP-2 dual agonist - Zealand Pharma; glucagon/GLP-1 agonists; ZP GG 72

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim; Zealand Pharma
  • Class Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Metabolic disorders
  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Denmark (SC)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Denmark (SC)
  • 28 Jul 2014 Preclinical trials in Cardiovascular disorders and Metabolic disorders in Denmark and Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top